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Abstract
Total elbow arthroplasty (TEA) is utilized in
the treatment of rheumatoid and post-traumat-
ic elbow arthritis. TEA is a relatively low vol-
ume surgery in comparison to other types of
arthroplasty and therefore little is known about
current surgical utilization, patient demo-
graphics and complication rates in the United
States. The purpose of our study is to evaluate
the current practice trends and associated in-
patient complications of TEA at academic cen-
ters in the United States. We queried the
University Health Systems Consortium admin-
istrative database from 2007 to 2011 for
patients who underwent an elective TEA. A
descriptive analysis of demographics was per-
formed which included patient age, sex, race,
and insurance status. We also evaluated the
following patient clinical benchmarks: hospital
length of stay (LOS), hospital direct cost, in-
hospital mortality, complications, and 30-day
readmission rates. Our cohort consisted of
3146 adult patients (36.5% male and 63.5%
female) with an average age of 58 years who
underwent a total elbow arthroplasty (159 aca-
demic medical centers) in the United States.
The racial demographics included 2334 (74%)
Caucasian, 285 (9%) black, 236 (7.5%)
Hispanic, 16 (0.5%) Asian, and 283 (9%) other
patients. The mean LOS was 4.2±5 days and
the mean total direct cost for the hospital was
16,300±4000 US Dollars per case. The overall
inpatient complication rate was 3.1% and
included mortality <1%, DVT (0.8%), re-opera-
tion (0.5%), and infection (0.4%). The 30-day
readmission rate was 4.4%. TEA is a relatively
uncommon surgery in comparison to other
forms of arthroplasty but is associated with low
in-patient and 30-day perioperative complica-
tion rate. Additionally, the 30-day readmission
rate and overall hospital costs are comparable
to the traditional total hip and knee arthroplas-
ty surgeries.
Introduction
Total elbow arthroplasty (TEA) is an effec-
tive procedure for the management of inflam-
matory and post-traumatic arthritis of the
elbow as well as severely comminuted distal
humerus fractures in low-demand individu-
als.1-4 TEA is a relatively uncommon arthroplas-
ty procedure in comparison to other joints and
therefore information regarding rates of uti-
lization, costs, and complications from large
nationwide databases are not widely available.
Obtaining and understanding this information
is important in an era of increasing cost con-
scious delivery of healthcare. A large, national-
ized inpatient registry for TEA is on the rise.
Several European registries exist for elbow
arthroplasty.5,6 No large registry for TEA is
available in the United States despite calls for
such a registry. Previous analysis of TEA uti-
lization and complication rates in the United
States have been limited to sampling of either
regional or national databases with limited
information. Using the National Inpatient
Sample database, Day et al.7 reported a 248%
increase of the number of primary TEA from
1993 to 2007 which equates to a 6.4% annual
procedure volume growth rate. However, their
study did not report the associated costs, 30-
day complication rates or the demographics of
patients undergoing TEA. Gay et al.8 reported
on the indications and reoperation rates for
TEA in New York State. The largest previous
cohort review occurred over a decade ago and
included 3500 TEA’s between 1988 and 2005.
Recent trends in the United States indicate an
increase in the number of TEA procedures per-
formed per year with a trend toward perform-
ing more procedures for trauma than for
inflammatory arthritis.8,9 To our knowledge,
there is no established national database
studying the epidemiology and 30-day compli-
cation rates or outcomes of patients undergo-
ing TEAs because majority of studies have
been performed at single institutions with
small numbers of patients. We isolated our
study to TEA procedures performed at academ-
ic medical centers in United States between
2007-2011. Our study intends to evaluate the
inpatient demographics, complications and
readmission rate of patients after TEA in major
academic centers across the United States. 
Materials and Methods
A national administrative database of aca-
demic medical centers that tracks patients and
hospital specific outcomes was used to charac-
terize in-patient trends and complications. The
University Health Systems Consortium (UHC)
is an alliance of the nation’s leading nonprofit
academic medical centers with 159 academic
medical centers and 261 affiliated hospital
members. UHC membership includes more
than 90% of the non-profit academic medical
centers in the United States. It provides
patient, hospital, and financial outcomes
across different centers. The data in the UHC
database is primarily acquired from submitted
UB-04 billing forms, similar to the forms sub-
mitted by hospitals for reimbursement on a
variety of disease conditions and surgical
treatments.
The UHC clinical data base resource manag-
er (CDB/RM) provides the following informa-
tion: synthetic hospital and surgeon identi-
fiers, including specialty, unique patient visit
identifiers, patient demographics, financials,
procedurals, and diagnostic information.
Morbidity and complication data are compiled
from the UHC morbidity profiler. Both cost and
charge information is reported in CDB/RM.
Charges are reported by each center and costs
are calculated using institution-specific cost-
to-charge ratios obtained from the depart-
ment-level Medicare cost reports. Federally
reported area wage indices are used to account
for regional- and center-specific cost varia-
tions that are not directly attributable to a cen-
ter. The UHC severity of illness score is a vali-
dated measurement tool for both risk adjust-
ment and predicted resource allocation. The
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UHC severity of illness score takes into
account several health-related patient vari-
ables including medical comorbidities, age,
and other relevant diagnoses.10 We queried the
UHC administrative database from 2007 to
2011 for adult patients ≥18 who underwent an
elective TEA. Elective total elbow arthroplasty
was defined by the type of admission (elective)
and International Classification of Diseases
book 9, and clinical modification procedural
codes (81.84). A descriptive analysis of demo-
graphics was performed which included
patient age, sex, race, and insurance status
(private, Medicaid, Medicare, government, and
other). The outcomes of interest were periop-
erative morbidity, hospital length of stay
(defined as the interval from the date of proce-
dure to the date of discharge), hospital direct
cost, index hospitalization survival, complica-
tions or inpatient mortality, and 30-day read-
mission rate. Cost was defined as an expense
that could be directly traced to the care of a
patient, whether it was services or supplies
rendered. 
Results
Between 2007 and 2011, 3146 TEAs were
performed and queried from the UHC adminis-
trative database from 159 different academic
medical centers across the USA. The mean and
standard deviation of surgical volume for indi-
vidual surgeons was 7±5 TEA performed annu-
ally. The average patient age was 58 years old.
64% of patients were female (Figure 1A). Of
the 3146 total elbow arthroplasties, the major-
ity of the cohort 2334 patients (74%) were
white, 285 (9%) were black, 236 (7.5%) were
Hispanic, 16 (0.5%) were Asian, and 9% were
other or unknown. Overall, 51% of the cohort
had private insurance, 41% had Medicare, and
8% had Medicaid (Figure 1B). At least 70% of
the cohort had one or more chronic medical
condition. The average length of stay post-
surgery was 4.23 days (Figure 2A). The mean
total direct cost for the hospital was
16,300±4000$ per case (Figure 2B). In hospital
mortality was less than 1% during the index
hospitalization. The overall complication rate
was 3.1% includes DVT (0.8%), re-operation
(0.5%), and infection (0.4%) (Figure 2C). The
30-day readmission rate was 4.4%. 
Discussion
Total elbow arthroplasty is an effective pro-
cedure for the treatment of patients with long
standing rheumatoid arthritis and other
degenerative conditions of the elbow and acute
trauma. However, as the results of this study
show, it is a relatively uncommon in surgery
with only 3146 TEA’s performed over a 5 year
period in comparison to higher volume arthro-
plasty such as total knee arthroplasty which is
performed at a rate of 700,000 annually in the
United States. As such, the information
regarding TEA utilization, demographics, cost
and complications are limited. Our study found
a steady increase in the number of TEA proce-
dures performed in the United States from
2007 to 2011 at around 600 to 700 TEA per year.
Day et al.7 reported the number of TEAs per-
formed in the United States increased at a rate
of 6.4% in annual procedural volume and 7.6%
in annual growth between 1993 to 2007. A
recent study analyzing the Norwegian
Arthroplasty Registry found a decreased num-
ber of TEAs performed per year in that particu-
lar country. The report indicated an increase in
the number of TEAs performed for traumatic
conditions, however the overall number of pro-
cedures decreased by 50% from 1994 to 2006.11
The overall decrease in TEA volume is thought
to be related to the decreased number of symp-
tomatic rheumatoid arthritis patients as a
result of advances in medical management,
specifically the introduction of immune modu-
lating or suppression medications such as TNF
(tumor necrosis factor) inhibitors. In 1994,
Kraay et al.12 reported 80% of total elbow
arthroplasties in their series were performed
secondary to rheumatoid arthritis. In contrast
to the above studies, Gay et al.8 using New York
State Department of Health database, found a
44% increase in the number of total elbow
                             Article
Figure 1. A) Gender demographics and B) insurance demograph-
ics of total elbow arthroplasty patients in the United States.
Figure 2. Average length of stay (A), cost (B) and complication
rates (C) of total elbow arthroplasty patients in the United States.
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arthroplasties performed per year. Their study
showed a decreasing trend in the number of
rheumatoid arthritis patients, but this
decrease in number was offset by a 132%
increase in the number of total elbow arthro-
plasty procedures performed for trauma or
elbow fracture diagnosis. 
In our study, the most common group of
patients undergoing total elbow arthroplasty is
primarily white females, which is consistent
with previous epidemiological studies.9 This is
likely related to increased number of osteo-
porotic traumatic elbow fractures seen in this
patient population. The average age of 58
years old in our study is also similar to what is
reported in the literature.8 Our database found
the annual surgical volume for individual sur-
geons who performed total elbow arthroplas-
ties was 7±5 procedures. Given the overall low
volume of TEA surgery, we were unable to eval-
uate any correlation between surgeon experi-
ence and outcomes or complications. Though
previous studies have found differences in
complication rates at 6.8% for inexperienced
surgeons compared to 2.8% for experienced
surgeons.8 The average length of stay (LOS)
was 4.23 days and did not vary significantly
during the time period studied. The average
LOS indicates that acute post-surgical recovery
can be a difficult and lengthy process for these
patients that include pain control, physical and
occupational therapy, and rehab placement. In
our study, approximately half of the patients
had Medicare and/or Medicaid; the other half
was comprised of private (32.3%), military
(1%), worker’s compensation (6.7%), and self-
pay (8.6%). The average cost of total elbow
arthroplasty including hospital stay was
16,300±4000$. Day et al. reported the average
hospital charges in 2007 for a TEA in the
United States was $51,970 (range of $46,338 to
$57,601) including a surgeon’s fee of $1524
(range of $1228 to $1842).7 The difference in
cost between this database study and the
above reported values is likely due to the loca-
tion, type of charges reported and hospital sys-
tems.
Common complications of total elbow
arthroplasty reported in clinical studies
include ulnar neuropathy (up to 40%), aseptic
loosening (7-15%), periprosthetic fracture (5-
29%), implant failure, infection (3-8%), triceps
insufficiency (2-8%) and instability.1,2,4,8,13-16
The Coonrad-Morrey total elbow prosthesis
(Zimmer, Warsaw, IN, USA) is one of the most
commonly used semi-constrained devices.
Previous studies have reported >80% of the
patients had good to excellent results, which
was associated with good elbow function and
pain relief. In our study, the overall inpatient
and 30-days complication rate associated with
TEA is 3.1%. The rate of deep vein thrombosis
is 0.8%, re-operation is 0.5% and infection is
0.4%. The 30-day re-admission rate is4.4%. In
comparison to other cohorts of hip fracture
and arthroplasty patients, previous studies on
post-operative hip fracture patients, the 28 day
re-admission rate was 11.8% and the most
common causes were pneumonia (27.3%),
dehydration and renal dysfunction (18.2%)
and deteriorating mobility (18.2%).17 In the
total hip arthroplasty population, previous
studies have shown the 28 day readmission
rate to be 8.5% and the main reasons for re-
admission to include thromboembolic disease
(2.5%), atraumatic dislocation (1.4%), wound
complications (1.2%) and post operative
swelling (1.8%)18. Frankle et al. reported of a
12% readmission rate in patients who had a
total elbow arthroplasty for comminuted distal
humerus fractures.19 Our reported 0.8% rate of
deep venous thrombosis is consistent with pre-
vious reports of 0.3% rate of pulmonary emboli
in patients who have undergone a total elbow
arthroplasty.8 We found an in-hospital infec-
tion rate of 0.4% which likely only accounts for
acute post-operative infections. Reported long-
term infection rates range from 0 to 8.3% with
higher rates in patients with inflammatory
arthritis.2-4,8,12,20-23 The causes of readmission
should be identified and addressed in future
studies to improve total elbow arthroplasty out-
comes. Overall, there are many inconsisten-
cies in the literature for total elbow arthroplas-
ty with a lack of standardization in outcome
measures.24 Commonly cited functional out-
comes include the Mayo Elbow Performance
Score, the Dash score, SF-36 score, and the
HSS scoring system for total elbow arthroplas-
ty. We were unable to gather any long-term
data including functional outcomes and pain
scores from the University Health Systems
Consortium database. Reported long-term
complication rates in the existing literature
range from <1-41.7%.1,2,4,8,13-16 Our inpatient
short-term 30-day complication rate of 3.1% is
similar to a report of <1% perioperative com-
plications in a study of 3617 patients by Cook
et al.9 These low complication rates may reflect
technical improvements of implants or of
improved surgical experience in surgeons who
work at academic centers. According to a
review of a New York State registry, Gay et al.8
reported that less than 10% of TEAs were per-
formed by experienced surgeons. Given the
paucity of outcomes data for TEA in the litera-
ture, the authors feel that there is a need for a
national total elbow registry to collect uniform
indications for surgery, functional outcomes
and complication data.
There are several limitations of our study
inherent to a retrospective review of an inpa-
tient multicenter database. Our data is subject
to reporting bias and we do not have informa-
tion regarding indications for surgery or rea-
sons for readmission. Additionally, we are
unable to gather outcomes data or report the
rate of certain pertinent complications related
to TEA such as post-operative ulnar neuropa-
thy and instability.20,25 Additionally, there is no
data present from the UHC that describes the
type of implants utilized (type of constraint or
manufacturer) or the level of experience of the
attending surgeon performing the procedure.
Riedel et al.24 stated that there is a lack of con-
sensus among published total elbow arthro-
plasty papers that makes it difficult to compare
long term outcomes. In order for comparison
across current studies that exist and for future
data gathering purposes, it is important to
report a universally accepted outcome score
that focuses on epidemiology, pain, function,
and complication rates. 
Conclusions
Total elbow arthroplasty performed in
United States university medical centers is
associated with low in patient complication
rates that include DVT 0.8%, re-operation
0.5%, and infection 0.4%. 4.4% of patients were
readmitted to the hospital within 30 days of the
index procedure. The overall 30-day complica-
tion rate is 3%. The average hospital stay is 4
days with a total cost of 16,300±4000$ per
case. White females represent the vast majori-
ty of patients undergoing total elbow arthro-
plasty and private insurance or Medicare typi-
cally pays for the procedures. Future studies
should focus on indications for total elbow
arthroplasty with specific outcome scores
reported in order to universally apply data to
future cases. 
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